Regulatory · source year

2018 regulatory records

38 selected, source-linked regulatory records dated 2018. This is selective source coverage, not a complete timeline.

Dated records

38 selected records.

Peptide profiles

21 connected profiles.

Cited sources

38 distinct public records.

Cited chronology

Dated source records

All record types in 2018 →

December 2018

6 records

Etelcalcetide

Federal Register notice 2018-28221

The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide.

Source: Federal Register via GovInfo ↗

→

Linaclotide

Federal Register notice 2018-28213

The Federal Register published notice 2018-28213, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Product-Specific Guidance for Linaclotide; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.

Source: Federal Register via GovInfo ↗

→

Lixisenatide

Federal Register notice 2018-27805

The Federal Register published notice 2018-27805, attributed to FDA and its parent HHS department, on 2018-12-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

Source: Federal Register via GovInfo ↗

→

Plecanatide

Federal Register notice 2018-26289

The Federal Register published notice 2018-26289, attributed to FDA and its parent HHS department, on 2018-12-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.

Source: Federal Register via GovInfo ↗

→

November 2018

7 records

Plecanatide

Federal Register notice 2018-25950

The Federal Register published notice 2018-25950, attributed to FDA and its parent HHS department, on 2018-11-29. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.

Source: Federal Register via GovInfo ↗

→

Calcitonin salmon

Federal Register notice 2018-25187

The Federal Register published notice 2018-25187, attributed to FDA and its parent HHS department, on 2018-11-19. Its official title is “Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

October 2018

3 records

Abaloparatide

Federal Register notice 2018-22956

The Federal Register published notice 2018-22956, attributed to FDA and its parent HHS department, on 2018-10-22. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,” and PeptideScanner's exact reviewed identity mapping connects the document to Abaloparatide.

Source: Federal Register via GovInfo ↗

→

September 2018

1 record

August 2018

2 records

Vasopressin

Federal Register notice 2018-18614

The Federal Register published notice 2018-18614, attributed to FDA and its parent HHS department, on 2018-08-28. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

July 2018

7 records

Glatiramer acetate

Federal Register notice 2018-15735

The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

Source: Federal Register via GovInfo ↗

→

June 2018

3 records

April 2018

2 records

Lixisenatide

Federal Register notice 2018-07256

The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

Source: Federal Register via GovInfo ↗

→

March 2018

3 records

Oxytocin

Federal Register rule 2018-06358

The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

February 2018

3 records

Dalbavancin

Federal Register notice 2018-02768

The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→

Leuprolide

Federal Register notice 2018-02667

The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

January 2018

1 record

Lutetium Lu 177 dotatate

Drugs@FDA application NDA208700

The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→